CJC - 1295 + IPAMORELIN

CJC-1295 + Ipamorelin is a synergistic peptide combination widely studied for its ability to stimulate endogenous growth hormone (GH) secretion through complementary mechanisms, while preserving physiological pulsatility[1][6].

• CJC-1295 is a growth hormone–releasing hormone (GHRH) analog that prolongs GH signaling by increasing the half-life of native GHRH activity.

• Ipamorelin is a selective ghrelin receptor (GHS-R) agonist that stimulates GH release with minimal impact on cortisol or prolactin levels compared to earlier secretagogues[2][4].

Together, this combination is explored in research contexts focused on body composition, recovery, sleep quality, and metabolic support, offering a balanced GH-stimulation profile without direct exogenous GH administration[3][5].

Administration (research setting):
Typically studied via subcutaneous injection, often timed to support natural GH pulses (e.g., evening or fasting windows), depending on protocol design.

Reconstitution:
Add 2.0 mL bacteriostatic water → 5 mg/mL total peptide concentration (≈5000 mcg/mL combined).

Common research ranges:

• CJC-1295: 100–300 mcg per administration

• Ipamorelin: 100–300 mcg per administration
  (often used together in equimolar or matched doses, 1–2 times daily, depending on study objectives)[1][4]

Measurement guide:
At 5 mg/mL, 1 unit on a U-100 insulin syringe (0.01 mL) ≈ 50 mcg, enabling precise and flexible measurement.

Storage:
Lyophilized vial: store frozen at −20 °C (−4 °F).
After reconstitution: refrigerate at 2–8 °C (35.6–46.4 °F).
Avoid repeated freeze–thaw cycles to maintain peptide integrity and stability.